We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) today announced that they have entered into a new collaboration to accelerate clinical development of VX-770, a novel, oral drug candidate for the treatment of cystic fibrosis (CF).
The consumer affairs watchdog is extending an investigation into the country's drug pricing arrangements and plans to issue a final in-depth report in the first quarter of 2007, it said on Thursday.
The recent price reduction of Merck's HIV/AIDS antiretroviral (ARV) Stocrin -- a drug used by approximately 70,000 people each day in Kenya, Uganda, Tanzania and Rwanda -- may push other drugmakers to lower their ARVs, according to local reports.
The combination of Tomudex (raltitrexed) and Platinol (cisplatin) has been shown to decrease dyspnea (shortness of breath) in patients with malignant pleural mesothelioma (MPM), according to a study published in the Journal of Clinical Oncology.
Sales of Western-style pharmaceuticals in China totaled roughly $19.2 billion in 2005, according to a new study that forecasts the country will become the fifth-largest pharmaceutical market by the end of the decade and the world's largest market by 2050.
Taleo Corporation, the leading provider of talent management solutions, today announced it has completed implementation into eight countries of its solution with global pharmaceutical giant Roche.
European bourses were mixed Wednesday, with techs lower and investors cautious about US interest rates, while gains at Sanofi-Aventis lifted drug players.
Tripos, Inc., a leading provider of drug discovery chemistry and informatics products and services, today announced that Tripos Discovery Research Ltd. (TDR), based in Bude, England, has formed a new research collaboration with Cara Therapeutics, an emerging U.S. biotechnology company based in Tarrytown, N.Y. Cara is focused on developing novel therapeutics to treat medical conditions associated with pain and inflammation.
Ambrilia Biopharma Inc. (formerly Procyon Biopharma Inc.), a biotechnology company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today its fiscal 2005 results and the appointment of three new members to its Board of Directors.